Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ENTA
- Price
- 7.18
- Stock movement down
- -0.23 (-2.61%)
- Company name
- Enanta Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 183.64M
- Ent value
- 394.24M
- Price/Sales
- 2.72
- Price/Book
- 1.43
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -31.99%
- 3 year return
- -50.31%
- 5 year return
- -29.34%
- 10 year return
- -14.35%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENTA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.72 |
| Price to Book | 1.43 |
| EV to Sales | 5.83 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 21.38M |
| EPS (TTM) | -5.48 |
| FCF per share (TTM) | -4.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 67.64M |
| Gross profit (TTM) | 66.37M |
| Operating income (TTM) | -121.69M |
| Net income (TTM) | -116.05M |
| EPS (TTM) | -5.48 |
| EPS (1y forward) | -3.23 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 98.13% |
| Operating margin (TTM) | -179.92% |
| Profit margin (TTM) | -171.58% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.23M |
| Net receivables | 38.65M |
| Total current assets | 299.85M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 376.65M |
| Accounts payable | 8.00M |
| Short/Current long term debt | 55.47M |
| Total current liabilities | 57.53M |
| Total liabilities | 247.84M |
| Shareholder's equity | 128.81M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -78.76M |
| Capital expenditures (TTM) | 17.95M |
| Free cash flow (TTM) | -96.71M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -90.09% |
| Return on Assets | -30.81% |
| Return on Invested Capital | -89.03% |
| Cash Return on Invested Capital | -74.20% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.84 |
| Daily high | 9.05 |
| Daily low | 8.52 |
| Daily Volume | 129K |
| All-time high | 126.37 |
| 1y analyst estimate | 17.67 |
| Beta | 0.88 |
| EPS (TTM) | -5.48 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Nov 2025 |
Downside potential
Loading...
Downside potential data
| ENTA | S&P500 | |
| Current price drop from All-time high | -93.20% | -1.46% |
| Highest price drop | -96.63% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -46.62% | -10.99% |
| Avg time to new high | 41 days | 12 days |
| Max time to new high | 1791 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
183.64M
Marketcap category
Small-cap
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Employees
131
Website
Investor relations
-
SEC filings
CEO
Jay R. Luly
Country
USA
City
Watertown
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page